CoChat
Sign Up
Cited by 245Patient-Provider Communication in HealthcareCancer survivorship and careBreast Cancer Treatment Studies

The DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.

Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use

Kahn, Katherine L., Schneider, Eric C., Malin, Jennifer L., Adams, John L., Epstein, Arnold M.·2007·Medical Care
DOI 10.1097/01.mlr.0000257193.10760.7f
Open this paper in CoChat — free account

Abstract

BACKGROUND: Among breast cancer patients, tamoxifen use is associated with reduced risk of disease relapse and death, but it is often difficult for women to sustain therapy during the 5 years required to obtain maximum benefit. OBJECTIVES: We sought to examine the influence of patient-centered care activities on ongoing tamoxifen use 4 years after initiation, we examined key components of patient-centered care and rates of ongoing tamoxifen. METHODS: Using a prospective cohort study that included observational data from the National Initiative for Cancer Care Quality (NICCQ), we studied 881 patients with stage I-III breast cancer who were registered with an initial diagnosis in 1998 by an American College of Surgeons-approved hospital cancer registry in 1 of 5 metropolitan areas, who initiated tamoxifen treatment. A patient survey and medical record abstraction were used as measurements. RESULTS: Among women who initiated tamoxifen, 79% were still taking it 4 years later. Other than older age and the severity of side effects, other demographic, clinical and cancer characteristics, and treatments did not predict ongoing tamoxifen use. In contrast, after adjusting for these factors, the proportion of patients with ongoing tamoxifen use was lower for patients reporting less support than needed (82% vs. 69%, P = 0.0051), less than wanted role in decision-making (80% vs. 70%, P = 0.0486), decision-making about tamoxifen without doctor input (79% vs. 64%, P = 0.0182), and for patients who weren't told about side effects in advance (82% vs. 72%, P = 0.0016). CONCLUSIONS: Although age and the severity of side-effects remain important, patient-centered care was a primary mediator of patient adherence to ongoing cancer treatment with tamoxifen.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.mlr.0000257193.10760.7f

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 245

Related

See all

Metadata

Authors
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M.
Affiliations
  • RAND Corporation (US)
  • Brigham and Women's Hospital (US)
  • Amgen (United States) (US)
Corresponding author
  • Kahn, Katherine L.
  • Adams, John L.
ORCID
Venue
Medical Care
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-05
Volume
45
Issue
5
Pages
431-439
ISSN
0025-7079 (ISSN-L)
DOI
10.1097/01.mlr.0000257193.10760.7f
OpenAlex
W1979710912
Cited by
245
References
44
Citations by year
2026: 3 · 2025: 11 · 2024: 6 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 13 · 2019: 10 · 2018: 17 · 2017: 18 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 29 · 2012: 14
FWCI
12.51
Type
journal article
Language
en
Open access
closed
Locations
  • Medical Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
breast cancer, tamoxifen, patient-centered care, medication adherence, patient support, shared decision-making, treatment side effects
MeSH terms
Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Medical Audit, Middle Aged, Neoplasm Staging, Patient Compliance, Patient Participation, Prospective Studies, Tamoxifen, Time Factors, United States, Cohort Studies, Patient-Centered Care, Health Care Surveys

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review